Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management

Bibliographic Information
Authors: Fahim S.A.; Attia Y.M.; Messiha A.; Nabawy A.Y.; Refaat F.; El-Maadawy W.H.
Journal: Biomedicine and Pharmacotherapy
Publisher: Elsevier Masson s.r.l.
Publication Date: December 2025
Volume / Issue: Volume 193
Article No.: 118731
ISSN: 7533322
DOI: 10.1016/j.biopha.2025.118731
Scopus: View on Scopus
PubMed: 41177120
Document Type: Review
Access: All Open Access; Gold Open Access
Authors and Affiliations
Fahim S.A., Department of Biochemistry, School of Pharmacy, Newgiza University (NGU), Newgiza, km 22 Cairo-Alexandria Desert Road, Giza, 12577, Egypt; Attia Y.M., Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Kasr Al Eini Street, Fom El Khalig, Cairo, Egypt; Messiha A., Virginia Hospital Center Department of Inpatient Pharmacy, Arlington, VA, United States; Nabawy A.Y., Department of Microbiology, School of Pharmacy, Newgiza University (NGU), Newgiza, km 22 Cairo-Alexandria Desert Road, Giza, 12577, Egypt; Refaat F., School of Pharmacy, New Giza University (NGU), New Giza, km 22 Cairo-Alexandria Desert Road, Giza, 12577, Egypt; El-Maadawy W.H., Pharmacology Department, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba (P.O. 30), Giza, 12411, Egypt
Abstract
Obesity and diabetes are two faces of the same coin, as both disorders are characterized by insulin action defects. The two gut-derived incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and Glucagon-like peptide-1 (GLP-1), play a crucial role in glycemic control. Semaglutide is a GLP-1 receptor agonist, while Tirzepatide acts as a dual agonist for the GLP-1 and GIP receptors. Despite its effectiveness in weight loss, various side effects were reported. This review seeks to explore post-marketing concerns regarding the long-term safety and tolerability of these drugs. Both drugs showed gastrointestinal issues, including nausea, vomiting, pancreatitis, and diarrhea. Moreover, bone remodeling, kidney and thyroid disorders were detected. Tirzepatide was preferred over the commonly used single GLP-1 RAs as it has less reported side effects and enhanced benefits in promoting bone formation and its protective renal effects, especially on decreasing albuminuria and eGFR slopes. © 2025 The Authors.
Keywords
GIP; Obesity; Semaglutide; Side effects; Tirzepatide; Animals; Anti-Obesity Agents; Clinical Decision-Making; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor Agonists; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; glucagon like peptide 1; glucagon like peptide 1 receptor agonist; incretin; insulin; antidiabetic agent; antiobesity agent; glucagon like peptide; adverse drug reaction; albuminuria; body weight loss; bone remodeling; clinical decision making; diarrhea; drug therapy; glycemic control; human; obesity management; ossification; pancreatitis; review; side effect; animal; comparative study
Citation Information
Scopus Citations: 7
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
